

You're invited to  
**SUSVIMO®: THE POWER OF  
CONTINUOUS DELIVERY**



Join us to learn about SUSVIMO for your patients with **nAMD** and **DME**.

Through a lively discussion, we will explore clinical findings of ARCHWAY and PAGODA Phase 3 trials, gain valuable insights from a patient case and explore key considerations for patient identification.


We look forward to welcoming you.

**WHERE**

**Oceans Prime  
2205 North West Shore Blvd  
Tampa, FL 33607**

**WHEN**

**Thursday, April 16, 2026  
7:00 pm ET**



Gregory Lee  
MD

901 Honeywell Prop  
Management Corp

For more information, please contact:  
Tonya Zwolenik or Charron Mundy

borock.tonya@gene.com  
mundy.charron@gene.com

To register for this event, please visit  
<https://genetechrsvp.com/> and enter LM26-1326

**Indications**

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.

**Important Safety Information**

**WARNING: ENDOPHTHALMITIS**

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

Please turn over for additional Important Safety Information and in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

### Important Safety Information (cont.)

#### Contraindications

- Ocular or periocular infections
- Active intraocular inflammation
- Hypersensitivity

#### Warnings and Precautions

- The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required
- Vitreous hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed
- Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first 2 postoperative months

#### Adverse Reactions

The most common adverse reactions (≥10%) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract, and vitreous hemorrhage.

You may report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in this invite and in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

Please note that this is a promotional educational program; CME credit will not be available.

Minnesota, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program. For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law, please visit <http://sunshine.gene.com>).

The meal value reported may vary by program location and be up to \$150 per person (exceptions may apply).

This event is sponsored by Genentech USA, Inc.  
No continuing education credits are offered with this program.

